Why the study?
Does pharmacotherapy improve outcomes in elderly patients aged 65 and older with congestive heart failure?
Does pharmacotherapy improve outcomes in elderly patients aged 65 and older with congestive heart failure?
This review highlights the lack of robust evidence for heart failure pharmacotherapy specifically in the elderly population, despite their increasing prevalence.
Answers are grounded in this paper and cite their sources.
Supports cautious HF therapy use in elderly; leaves open need for dedicated age-specific trials.
With longer life expectancy, as well as better survival rates after myocardial infarction, the population of elderly patients with congestive heart failure steadily increases. Large, randomized, placebo-controlled studies have shown significant beneficial effects for several classes of drugs (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, aldosterone antagonists) in patients with congestive heart failure. In most of these studies, however, elderly patients were either excluded or represented only a minority of the study population. Therefore, the treatment benefit for the large population of patients aged 65 and older is still not very well documented. In this paper, we critically review the current literature with regard to outcome of heart failure therapy in this particular subpopulation.
No takes yet. Share an insight, caveat, or question.
Burger et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: